Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $113K | $5.68K | $9.60K | $9.84K | $7.16K | $0.00 | $30.0K | $410K | $130K | $0.00 |
| Revenue growth | — | -94.9% | 68.9% | 2.5% | -27.3% | -100.0% | — | 1269.1% | -68.3% | -100.0% |
| Gross profit | $113K | $5.68K | — | — | — | — | — | — | — | — |
| Gross margin | 100.0% | 100.0% | — | — | — | — | — | — | — | — |
| Operating income | -$281K | -$1.85M | -$3.81M | -$3.30M | -$3.04M | -$2.60M | -$2.95M | -$931K | -$583K | -$272K |
| Operating margin | -249.5% | -32616.1% | -39670.1% | -33563.0% | -42524.1% | — | -9860.4% | -227.1% | -448.3% | — |
| Net income | -$307K | -$1.93M | -$3.78M | $1.13M | -$7.47M | -$3.19M | -$3.72M | -$3.71M | -$695K | -$314K |
| Net margin | -273.0% | -34022.5% | -39335.7% | 11510.4% | -104337.9% | — | -12428.2% | -904.6% | -534.5% | — |
| EPS (diluted) | $0.00 | -$0.02 | -$0.03 | $0.02 | -$0.10 | -$0.02 | -$3.59 | -$0.42 | -$0.02 | $0.00 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$120K | -$864K | -$1.97M | -$3.09M | -$2.77M | -$2.49M | -$1.68M | -$113K | -$244K | -$171K |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $19.1K | $1.39M | $1.39M | $266K | $778K | $1.39M | $118K | $130K | $26.4K | $15.1K |
| Total assets | $23.7K | $3.64M | $3.18M | $15.2M | $2.22M | $3.08M | $811K | $499K | $31.4K | $18.4K |
| Total liabilities | $491K | — | — | — | — | — | — | — | — | — |
| Shareholders' equity | -$467K | -$2.94M | $2.65M | $14.7M | $1.76M | $1.81M | $1.63M | -$2.02M | -$2.48M | -$2.50M |
| Retained earnings | -$1.59M | -$3.52M | -$7.30M | -$6.16M | -$13.6M | -$16.8M | -$20.5M | -$24.3M | -$25.0M | -$25.3M |
| Shares (wtd avg diluted) | 107M | 120M | 122M | 134M | 135M | 139M | 1.22M | 8.82M | 30.2M | 90.6M |
Every figure is extracted from CNBX Pharmaceuticals Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.